| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f7b665fb8f15d0e2b0911539d39f8a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2b239123909f7350e70f9743d0a1708 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 |
| filingDate |
2011-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a7850b49010c53f5b9b2a4a08b77c44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef201655323700d92a5034afd23f781a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_648feffc9f960e14bc51b3e8208fd8f3 |
| publicationDate |
2014-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2410733-B1 |
| titleOfInvention |
Vaccine compositions based on modified gp41 immunogens |
| abstract |
Vaccine compositions based on modified gp41 immunogens. # The invention relates to human immunodeficiency virus (HIV) immunogens based on epitopes of gp41 located in the proximal membrane extracellular region (MPER). The immunogens of the present invention are capable of inducing serum neutralizing activity. Various forms of these isolated immunogens are disclosed and exemplified. The isolated nucleic acid molecules that express relevant parts of these immunogens, as well as the vectors and host cells used for their production, are also within the scope of the invention. |
| priorityDate |
2010-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |